Following Johnson & Johnson’s $158 million resolution with Texas several states have demanded higher payments, leading the U.S. Justice Department to raise its demand to $1.8 billion to settle its claims of false and misleading marketing. Risperdal was initially approved for psychotic disorders, but J&J marketed it for bipolar disorder, dementia, mood and anxiety disorders and other unapproved uses. Other states have indicated potential interest in litigation as well.
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.